Business
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation
Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology Company Has a
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"\nOncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology\n\nCompany Has a Differentiated and Fast-growing, Commercial Drug Delivery Business; Significant Potential Upside from Immunotherapy Platform\n\nPost-transaction, Expects to be Fully Funded to Allow Key Data Read-Outs for Device and Immunotherapy Platform in Late 2024\n\nAccelerates Access to Resources to Drive Continued Commercialization of TriNav® Infusion System and Advance SD-101 Clinical Programs\n\nExpected Cash at Closing Includes Up to $50 Million from an Anticipated Convertible Note from Leading Institutional Investor\n\n DENVER & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--\nTriSalus Life Sciences® (the “Company” or “TriSalus”), a privately held oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors, today announced it has entered into a definitive merger agreement with MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech”), a publicly traded special purpose acquisition company. Upon the closing of the transaction, the combined company will be a publicly traded company and its common stock is expected to be listed on the NASDAQ Stock Exchange under the ticker “TLSI”. The transaction represents a post-transaction market capitalization of approximately $244.4 million for TriSalus upon closing.\n\nTriSalus Combines Proprietary Drug Delivery Technology and Therapeutics Platform to Drive Better Patient Outcomes\n\nTriSalus’ proprietary platform approach addresses immune dysfunction in liver and pancreatic tumors by combining its highly effective drug delivery technology with immunotherapeutics. The TriSalus platform comprises:\n\n\nTriNav® Infusion System: Launched in 2020, TriNav is an FDA-cleared device that is designed to administer established and emerging therapeutics, including SD-101, the Company’s investigational TLR9 agonist, to selected sites, including tumors in the liver with the ability to treat disease throughout the entire organ. TriNav is the latest TriSalus asset for the proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method of administration which has been shown to overcome intra-tumoral pressure through modulation of pressure and flow to inc...